Incyte raises 2024 sales forecast for top-selling drug Jakafi
Oct 29 (Reuters) -Incyte INCY.O beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.
Jakafi is approved for use in patients with two types of blood cancers called myelofibrosis and polycythemia vera (PV). The treatment is also approved for acute graft-versus-host disease (GVHD), in which the donor's bone marrow or stem cells attack the recipient's body.
The drug's sales have been especially driven by use among GVHD and PV patients. The company expects PV to become the largest contributor to Jakafi over time.
Incyte expects Jakafi sales in 2024 to be between $2.74 billion and $2.77 billion, compared with its previous forecast of $2.71 billion to $2.75 billion. Analysts on average expected $2.75 billion, according to data compiled by LSEG.
Sales from Jakafi rose 16% to $741 million during the third quarter, beating estimates of $725.2 million.
Total sales from Opzelura, used for the treatment of vitiligo and mild-to-moderate atopic dermatitis in patients 12 years and older, also jumped 52% to $139 million in the quarter. That also topped estimates of $130.8 million.
The drugmaker is banking on Opzelura's sales as it braces for a loss of exclusivity to Jakafi in 2028.
On an adjusted-basis, Incyte earned $1.07 per share in the quarter ended Sept. 30, in line with estimates.
Its total revenue came in at $1.14 billion, above estimates of $1.07 billion.
Reporting by Unnamalai L in Bengaluru; Editing by Shilpi Majumdar
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
